Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

PPLPHARMA's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 1.51100
forwardPE 40.22161
debtToEquity 69.51900
earningsGrowth 0.00000
revenueGrowth -0.00100
grossMargins 0.63485
operatingMargins 0.08799
trailingEps -2.47000
forwardEps 4.33200

Piramal Pharma Limited's current ratio of 1.511 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects Piramal Pharma Limited's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
Piramal Pharma Limited's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for Piramal Pharma Limited to sustain its current profitability.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

PPLPHARMA's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Analysts have shown a buy bias for PPLPHARMA, marking it as a favorable investment option. This could inspire investors to see PPLPHARMA as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.